 Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017326
|
| MeSH Number(s) |
E05.318.760.250.500.220 N05.715.360.775.088.500.220 N06.850.520.450.250.250.220
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in this website by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 2 | 3 | 5 | | 2006 | 0 | 3 | 3 | | 2007 | 0 | 2 | 2 | | 2008 | 0 | 2 | 2 | | 2009 | 0 | 3 | 3 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 2 | 3 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 4 | 4 | | 2016 | 0 | 6 | 6 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 5 | 6 | | 2019 | 0 | 5 | 5 | | 2020 | 0 | 4 | 4 | | 2021 | 1 | 7 | 8 | | 2022 | 0 | 8 | 8 | | 2023 | 0 | 2 | 2 | | 2024 | 0 | 5 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
Hoeper MM, Rosenkranz S, Badesch DB, Humbert M, Langleben D, McConnell JW, Hegab S, Rahner C, Richard JF, Ghofrani HA. Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies. Respir Med. 2025 01; 236:107910.
-
D?hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, Thirman MJ, R?cher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
Pavord ID, Rabe KF, Israel E, Szefler SJ, Brusselle G, Pandit-Abid N, Altincatal A, Chen Z, Amin N, Khan AH, Lederer DJ, Zhang Y, Rowe PJ, Deniz Y, Radwan A, Jacob-Nara JA, Busse WW. Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma. J Allergy Clin Immunol Pract. 2025 Jan; 13(1):132-142.
-
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabb? F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, J?nne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, Han J, Conde LG, Wright RS. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
-
Khader A, Zelnick LR, Sathe NA, Kestenbaum BR, Himmelfarb J, Johnson NJ, Shapiro NI, Douglas IS, Hough CL, Bhatraju PK. The Interaction of Acute Kidney Injury with Resuscitation Strategy in Sepsis: A Secondary Analysis of a Multicenter, Phase 3, Randomized Clinical Trial (CLOVERS). Am J Respir Crit Care Med. 2023 12 15; 208(12):1335-1338.
-
Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
-
Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res. 2022 12 15; 28(24):5272-5279.
-
Garcia-Cremades M, Vucicevic K, Hendrix CW, Jayachandran P, Jarlsberg L, Grant R, Celum CL, Martin M, Baeten JM, Marrazzo J, Anderson P, Choopanya K, Vanichseni S, Glidden DV, Savic RM. Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Clin Infect Dis. 2022 11 30; 75(11):1873-1882.
-
Sahin IH, Lin Y, Yothers G, Lucas PC, Deming D, George TJ, Kopetz S, Lieu CH, Dasari A. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. Oncology (Williston Park). 2022 10 07; 36(10):604-608.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|